Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693986 · ClinicalTrials.gov registry record · Phase 1
Adenovirus (RGDCRAdCOX2F)
A Phase 1 study of Adenocarcinoma of Pancreas, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06693986 is a Phase 1 study of Adenocarcinoma of Pancreas that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06693986, a Phase 1 study of Adenocarcinoma of Pancreas, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.
Conditions Studied
Interventions
- BIOLOGICAL Replicative Adenovirus Vector (RGDCRAdCOX2F)
Study Locations (1)
Minnesota
- Masonic Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-12-27 |
| Est. Completion | 2029-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06693986
The ClinicalTrials.gov registry entry for NCT06693986 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adenocarcinoma of Pancreas appearing as the primary indexed condition, and to 1 intervention - of which Replicative Adenovirus Vector (RGDCRAdCOX2F) is the first listed.
NCT06693986 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06693986 about?
NCT06693986 is a clinical study titled "Adenovirus (RGDCRAdCOX2F)". This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum des...
What is the current status of trial NCT06693986?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-12-27. Estimated completion is 2029-10-15.
What conditions does trial NCT06693986 study?
This clinical trial studies the following conditions: Adenocarcinoma of Pancreas.
What interventions are being tested in trial NCT06693986?
The interventions under investigation include: Replicative Adenovirus Vector (RGDCRAdCOX2F) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06693986?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693986 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.